RecruitingPhase 4NCT05412394
Once Weekly Infant Corticosteroid Trial for DMD
Phase-2 Trial of 5mg/kg/Week Prednisolone in Young Boys With DMD
Sponsor
Anne M. Connolly
Enrollment
26 participants
Start Date
Apr 30, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.
Eligibility
Sex: MALEMin Age: 1 MonthMax Age: 30 Months
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Prednisolone for people with duchenne muscular dystrophy. The study is currently recruiting participants at 4 locations. People eligible for this study include men aged 1 Month to 30 Months.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPrednisolone
Liquid, 5mg/kg per week, for one year
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05412394
Related Trials
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
NCT046266747 locations
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT0728718921 locations
Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
NCT07766980
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
NCT071606346 locations
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT0681738210 locations